Kaida BioPharma Launches Social Media Channels
September 18, 2024 10:00 ET
|
Kaida Biopharma
Company dedicated to providing a new hope for patients with treatment-resistant gynecological cancers Lead program, KAD101 for the treatment of ovarian cancer rapidly advancing towards Phase 1...
United Kingdom Hearing Aid Devices Market Analysis, Competition, Forecasts & Opportunities, 2019-2023 & 2024-2029
September 18, 2024 04:03 ET
|
Research and Markets
Dublin, Sept. 18, 2024 (GLOBE NEWSWIRE) -- The "United Kingdom Hearing Aid Devices Market, By Region, By Competition, Forecast & Opportunities, 2019-2029F" report has been added to ...
Robot Industries Officially Opens its Main Global Headquarters in Berlin
September 17, 2024 01:45 ET
|
Robot Industries
Berlin, Germany, Sept. 17, 2024 (GLOBE NEWSWIRE) -- With great excitement, Robot Industries announces that it has shifted its global headquarters to Berlin, Germany. This step is an important...
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
September 04, 2024 09:25 ET
|
Hepion Pharmaceuticals, Inc.
KIRYAT ONO, ISRAEL and EDISON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product...
Cummins Joins SDVerse as a Premier Partner of its One-of-a-Kind Automotive Software Marketplace
July 24, 2024 13:00 ET
|
SDVerse
DETROIT, July 24, 2024 (GLOBE NEWSWIRE) -- SDVerse, a marketplace for buyers and sellers of automotive software, on July 24th, 2024, announced that global power technology leader Cummins Inc. has...
Brick Technology acquires event charging provider Volt in a step to consolidate the market
July 23, 2024 11:14 ET
|
Brick
Brick Technology AB acquires Volt ApS, enhancing its event charging provider services and expanding globally.
Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement
July 22, 2024 08:00 ET
|
Hepion Pharmaceuticals, Inc.
Pharma Two B Ltd. (“Pharma Two B”) has entered into a merger agreement with Hepion Pharmaceuticals, Inc. (“Hepion”) (Nasdaq: HEPA)Immediately upon completion of the merger, current Pharma Two B...
[Latest] Global Unified Endpoint Management Market Size/Share Worth USD 23.6 Billion by 2033 at a 22.7% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
July 18, 2024 12:30 ET
|
Custom Market Insights
Austin, TX, USA, July 18, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Unified Endpoint Management Market Size, Trends and Insights By Component...
USI Insurance Services Launches Ask V, the Next Generation in Industry Vertical Innovation & Solutions
July 12, 2024 07:00 ET
|
USI Insurance Services
VALHALLA, N.Y., July 12, 2024 (GLOBE NEWSWIRE) -- USI Insurance Services (“USI”), a world leader in risk management, employee benefit and retirement plan consulting, today announced the launch of...
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease
July 09, 2024 20:00 ET
|
Io Therapeutics, Inc.
Io Therapeutics presented data on the potential of IRX4204 for treatment of aging-related neurodegeneration, Parkinson's disease, and Alzheimer's disease